Cystic Fibrosis organisations in Australia provide support and services to people with Cystic Fibrosis (CF) and their carers and families. This is complemented by a commitment to research and a quality improvement program focussing on improved clinical care for people with CF.
Every four days a baby is born in Australia with cystic fibrosis (CF) and more than one million Australians are carriers of cystic fibrosis. Cystic Fibrosis Australia (CFA) is committed to improving clinical practice and patient outcomes through its quality improvement programmes and research with the aim of extending life expectancy from 47 to 55 years by 2025.
Cystic Fibrosis is a recessive genetic condition. It primarily affects the lungs and digestive system because of a malfunction in the exocrine system, responsible for producing saliva, sweat, tears and mucus.
In addition to working for a cure, Cystic Fibrosis Australia also provides support and advocacy to improve the lives of people with cystic fibrosis. Get involved by raising awareness about CF, participating in a fundraising event or volunteering.
Cystic Fibrosis Australia has established a consistent approach to advocacy across Australia and is now a subject matter expert for government, industry and the media.
The Australian Cystic Fibrosis Research Trust (ACFRT) is managed by Cystic Fibrosis Australia (CFA). Since 1989 it has funded more than 300 projects valued at over $6,000,000.
Visit the media room to browse through number of resources including media representatives, press releases and reports.
Clinical trials are listed below.
OtherEnrolling Location: Multiple US locations
Study of 4D-710 in Adults with Cystic Fibrosis (4DMT 4D-710-C001) , protocol number 4DMT 4D-710-C001 NCT05248230
This study will test the safety and tolerability of 4D-710, an investigational gene therapy, in adults with CF who are not eligible for or are unable to tolerate CFTR modulator therapy.
Age:
18 Years and Older
Mutation(s):
No Mutation Requirement
FEV1% Predicted:
50-100%
Number of Visits:
11
Length of Participation:
2 Years
Anti-InfectiveEnrolling Location: USA
Study of Lefamulin in Adults with CF (Nabriva NAB-BC-3781-1014) , protocol number Nabriva NAB-BC-3781-1014 NCT05225805
This study will look at the safety of and how the body processes lefamulin, a drug intended to treat infections in the lung. This study is for adults with CF.
40% or greater
6
13 days
Nutritional-GIEnrolling Location: Multiple care centres across the US
Study to evaluate Creon in adults with cystic fibrosis or chronic pancreatitis (AbbVie M21-432 ) , protocol number NCT05069597
This study will look at the symptoms of exocrine pancreatic insufficiency (EPI) in adults with cystic fibrosis or chronic pancreatitis treated with Creon with an alternate source of active drug. Creon is a drug approved to treat EPI.
No FEV1 Limit
3
142 days
Anti-InflammatoryEnrolling Location: Multiple US Centres
Study of INS1007/brensocatib tablets in adults with CF (Insmed INS1007-211) , protocol number NCT05090904
This study will look at the safety, tolerability, and how the body processes INS1007/brensocatib tablets, a drug intended to reduce inflammation.
40 to 90%
8
56 days
Restore CFTR FunctionEnrolling Location: Multiple US Centres
Study of VX-121 in people with CF ages 12 years and older who have either two copies of the F508del mutation, one copy of the F508del mutation and one copy of a gating or residual function mutation, or no copies of the F508del mutation and at least one other triple combination responsive CFTR mutation (Vertex VX20-121-103) , protocol number NCT05076149
This study will look at the safety and effectiveness of VX-121/tezacaftor/deutivacaftor, a drug combination intended to help CFTR protein function closer to normal. This study will test once-a-day dosing by using an active comparator. This means that some participants will receive the study drug or a placebo in the morning, and others will receive Trikafta®(elexacaftor/tezacaftor/ivacaftor) or a placebo in the morning and ivacaftor or a placebo in the evening. Researchers will test the effectiveness of the VX-121/tezacaftor/deutivacaftor combination by measuring changes in lung function and sweat chloride. This study may require lung function tests, sweat tests, blood draws, and/or other measures.
12 Years and Older
Not specified
40 - 90%
10
64 weeks
Restore CFTR FunctionEnrolling Location: Multiple US locations
Study of VX-121 in people with CF ages 12 years and older who have one copy of the F508del mutation and one copy of a minimal function mutation (Vertex VX21-121-102) , protocol number Vertex VX-21-121-102 NCT05033080
This study will look at the safety and effectiveness of VX-121/tezacaftor/deutivacaftor, a drug combination intended to help CFTR protein function closer to normal.
One Copy F508del
19
Anti-InfectiveEnrolling Location: Not specified
Study to evaluate nebulized BX004-A in adults with cystic fibrosis and chronic Pseudomonas aeruginosa (BiomX Phase 1b/2a) (BiomX BMX-04-001 Part 1) , protocol number NCT05010577
This study is testing the safety and tolerability of nebulized BX004-A, a bacteriophage drug intended to treat infections in the lung. Bacteriophages are specialized viruses that kill very specific bacterial strains. Multiple doses of the drug will be tested in adults with cystic fibrosis and chronic Pseudomonas aeruginosa (PsA) to find the best dose.
192 days
Study to evaluate nebulized BX004-A in adults with cystic fibrosis and chronic Pseudomonas aeruginosa (BiomX Phase 1b/2a) (BiomX BMX-04-001 Part 2) , protocol number NCT05010577
7
189 days
BehavioralRecruiting Location: Hobart, Tasmania
Impact of Beam Feel Good Website for individuals with cystic fibrosis (CF) , protocol number ACTRN12621000725864
Cystic Fibrosis (CF) is a chronic, life limiting condition, diagnosed usually at birth and is an autosomal recessive disease. Recent studies have indicated many adults with CF have strong beliefs that exercise may be equal or superior to other traditional forms of airway clearance as the mainstay for treatment. A lack of exercise in a daily regimen for an individual with CF has been associated with increased hospitalisations, poorer health outcomes including decline in lung function and decreased quality of life.
16 Years to 65 Years
Restore CFTR FunctionEnrolling Location: Multiple care centres across the US
Study to evaluate inhaled AR-501 in healthy adults and adults with cystic fibrosis and Pseudomonas aeruginosa (Aridis AR-501-001 MAD cohorts) , protocol number (Aridis AR-501-001 MAD cohorts) NCT03669614
This study is testing inhaled AR-501, a drug intended to treat infections in the lung. The study will measure the drug’s safety, how well it works, and how the body processes it. Multiple doses of AR-501 will be tested in both healthy adults and adults with cystic fibrosis who are infected with Pseudomonas aeruginosa to find the best dose.
45% or greater
6 Weeks